Century Therapeutics (IPSC) investor relations material

Strategic focus and pipeline evolution

• Accelerating core programs, including CNTY-101 (NK cell-based, CD19 CAR) and CNTY-308 (iPSC-derived alpha-beta T cells), with clinical and preclinical trials in autoimmune and B-cell-mediated diseases.

• CNTY-308 is in IND-enabling studies, targeting clinical entry mid-next year, representing a first in generating autologous-like T cells from iPSC.

• A new non-immune cell program is advancing rapidly, positioned in a non-competitive space.

• Restructuring has focused resources on key assets and extended cash runway through 2027.

Technological advancements and alloevasion platform

• Industry-leading alloevasion technology has evolved from 1.0 (in CNTY-101) to 5.0 (in CNTY-308 and preclinical programs), providing robust immune evasion.

• Alloevasion 5.0 includes CD300A “taser” for universal NK cell defense and an IgG-degrading protease for humoral protection.

• These edits enable off-the-shelf cell therapies with enhanced persistence and reduced need for lymphodepletion.

• Proprietary differentiation process yields tunable mixtures of CD4 and CD8 T cells, matching autologous CAR T efficacy.

Clinical and preclinical data highlights

• iPSC-derived T cells show comparable efficacy, proliferation, and persistence to autologous CAR T cells in preclinical models, including durable tumor control and re-challenge response.

• NK cell-based CNTY-101 is in two clinical trials (Calypso and Caramel) for autoimmune diseases, with flexible dosing and strong safety profile.

• Deep, sustained B cell depletion and tissue penetration observed in B cell malignancy and autoimmune trials, with alloevasion enabling persistence without lymphodepletion.

• Data readouts from Calypso are expected this year, with aggregation of data from both trials as possible.